Lycera appoints Jeffrey Wilkins as chief medical officer
US oncology and autoimmune biopharma company Lycera has appointed Jeffrey Wilkins to the newly-created chief medical officer position.
He will lead the development pipeline of immune modulators, in which the most advanced candidate is an ATPase modulator being developed to treat inflammatory bowel disease, which is expected to enter clinical testing in the second quarter of 2015.
Paul Sekhri, chief executive of the company, said: "We are delighted to welcome Jeff at an important time for the company, as we plan to advance multiple product candidates into the clinic in the near term. With over 15 years of clinical research experience, Jeff possesses significant expertise and experience in developing and designing clinical trials in all stages of drug development through market launch. He will no doubt play a pivotal role in the progress and success of our product candidate programs."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze